argenx SE logo
argenx SE ARGX
$ 940.88 -0.73%
report update icon

Quarterly report 2025-Q4
added 11-14-2026

argenx SE Net Income | ARGX

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income argenx SE

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1.29 B 833 M -295 M -710 M -408 M -529 M -163 M -66.6 M -28.1 M -21.4 M -15.3 M -10.3 M -6.13 M -9.7 M -3.46 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.29 B -710 M -9.38 M

Quarterly Net Income argenx SE

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
1.29 B 415 M 833 M -32.5 M -295 M -123 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
1.29 B -295 M 348 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Jaguar Health Jaguar Health
JAGX
-54 K $ 0.35 -8.69 % $ 816 K usaUSA
Arvinas Arvinas
ARVN
-81 M $ 6.77 -0.73 % $ 480 M usaUSA
Cerus Corporation Cerus Corporation
CERS
-15.6 M $ 1.95 2.63 % $ 372 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
-80 M $ 21.03 1.82 % $ 2.08 B usaUSA
Inhibrx Inhibrx
INBX
-241 M $ 68.87 -7.16 % $ 3.25 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
771 M $ 68.76 0.12 % $ 29.6 B usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
-11.4 M $ 3.24 8.0 % $ 150 M israelIsrael
Revolution Medicines Revolution Medicines
RVMD
-1.13 B $ 159.7 -1.84 % $ 30.4 B usaUSA
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
-114 M - - $ 459 M usaUSA
Legend Biotech Corporation Legend Biotech Corporation
LEGN
-297 M $ 16.25 0.87 % $ 5.99 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
-17.4 M $ 1.91 -1.55 % $ 263 M usaUSA
Krystal Biotech Krystal Biotech
KRYS
205 M $ 314.77 5.43 % $ 9.11 B usaUSA
Kura Oncology Kura Oncology
KURA
-279 M $ 7.34 -2.07 % $ 644 M usaUSA
Inhibikase Therapeutics Inhibikase Therapeutics
IKT
-48.3 M $ 1.39 0.36 % $ 137 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
-221 K $ 5.31 -3.45 % $ 387 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
-20 M $ 0.27 -3.26 % $ 45 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
-85 M $ 1.69 3.37 % $ 79.2 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
-15.3 M $ 10.19 0.22 % $ 805 M usaUSA
SIGA Technologies SIGA Technologies
SIGA
23.3 M $ 2.81 2.75 % $ 201 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
-14.3 M $ 2.66 -0.19 % $ 32.8 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
-26 M - -5.76 % $ 99.8 M usaUSA
Innoviva Innoviva
INVA
271 M $ 18.36 0.3 % $ 1.24 B usaUSA
BioCardia BioCardia
BCDA
-8.23 M $ 0.77 -2.06 % $ 5.13 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
-21.8 M - 0.11 % $ 419 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
-285 M $ 8.55 -7.07 % $ 741 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-12.1 M $ 1.72 -7.77 % $ 11 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
-6.63 M - -3.90 % $ 97.2 M chinaChina
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
-129 M $ 7.66 -4.25 % $ 673 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
75.3 K $ 3.9 0.78 % $ 161 M israelIsrael
Certara Certara
CERT
-1.6 M $ 11.25 1.72 % $ 1.8 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
-5.02 M $ 0.63 -4.8 % $ 408 K israelIsrael
Intec Pharma Ltd Intec Pharma Ltd
NTEC
-14.1 M - -12.45 % $ 17.7 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
-11 M $ 13.74 6.89 % $ 197 M usaUSA
Prothena Corporation plc Prothena Corporation plc
PRTA
-244 M $ 8.38 1.39 % $ 451 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
-12.6 M $ 0.46 2.6 % $ 3.01 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
-30.8 M $ 3.0 2.92 % $ 192 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
-13.6 M $ 1.7 -2.3 % $ 2.23 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
99.7 M $ 67.94 -3.04 % $ 7.06 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
-193 M - -3.47 % $ 164 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
-6.21 M $ 2.84 -0.7 % $ 1.93 M chinaChina
Genprex Genprex
GNPX
-16.2 M $ 1.73 3.56 % $ 1.61 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
-45.1 M - 1.52 % $ 136 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
108 B $ 21.27 -1.71 % $ 33.6 B japanJapan
Protara Therapeutics Protara Therapeutics
TARA
-57.4 M $ 2.33 0.22 % $ 99.8 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-49.2 M $ 1.0 -24.81 % $ 89.6 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
-16.3 M - -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
349 M $ 61.57 5.22 % $ 11.8 B usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
182 M $ 72.74 0.15 % $ 11.3 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
-10.3 M $ 0.91 6.35 % $ 4.98 M usaUSA